Gene Therapy to Target CD19 for Hematological Tumors is under clinical development by Chengdu USino Technology Biology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 for Hematological Tumors’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD19 for Hematological Tumors overview
Gene therapy is under development for the treatment of relapsed/refractory hematologic malignancies, including CD19 positive B-cell acute lymphoblastic leukemia (B-ALL), B-cell chronic lymphoblastic leukemia (B-CLL), and B-cell lymphoma. It is administered through parenteral route. The therapeutic candidate comprises genetically modified cord blood derived T cells from healthy donor, expressing chimeric antigen receptors (CAR) targeting cells expressing CD19 (universal anti-CD19 CAR-modified AT19 cells).
For a complete picture of Gene Therapy to Target CD19 for Hematological Tumors’s drug-specific PTSR and LoA scores, buy the report here.